Zydus Lifesciences Ltd (Zydus Lifesciences) is a life sciences company that focuses on the discovery, development, manufacturing, and marketing of healthcare therapies. The company's product portfolio includes finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. Zydus serves diverse customer needs across the globe, supplying its products in the US, India, Europe, and emerging markets, including countries in Latin America, the Asia Pacific region, and Africa.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Zydus Lifesciences focuses on innovative research and development (R&D) strategies to enhance healthcare accessibility. The company addresses critical needs through sustainable solutions, ensuring the availability of essential medications at affordable prices, thus improving health outcomes for underserved populations. Zydus Lifesciences' R&D efforts encompass the development of liquid oral solutions for geriatric and pediatric patients with dysphagia, pioneering generics to ensure an affordable drug supply, and creating India's first oral therapy for anemia associated with chronic kidney disease (CKD). The company is also actively collaborating with strategic partners to expand access to vaccines and biological products across both emerging and developed markets, enhancing the global availability of essential healthcare interventions. The Zydus Research Center (ZRC) is a dedicated research arm of the company that is involved in drug discovery and development from concept to IND-enabling preclinical and clinical studies. The Pharmaceutical Technology Center (PTC) is engaged in the development of pharmaceutical technologies and formulations. The Zydus Active Pharmaceutical Ingredients (API) Park focuses on the development and production of active pharmaceutical ingredients. Vaccine Technology Center (VTC) specializes in the development and manufacturing of various vaccine products. In FY2025, the company spent INR18,555 million on its R&D activities, which as a percentage of revenue stood at 8% and grew 42% YoY. As of March 2025, the company had seven R&D centers dedicated to NCEs, APIs, generics, vaccines, biosimilars, and wellness products. As of March 2025, the company had 86 filed patents and 48 patents granted, including 25 in NCE, seven in biotechnology and NDDS, one in Medical technology, two in clinical research, and six in API.